Curatis will apply for a Biologic License for C-PTBE-01 in the USA - this will significantly increase the duration of market protection in the USA in the event of approval
Curatis Holding (SIX:CURN) has explored in detail which regulatory pathway should be pursued in view of a possible approval of C-PBTE-01 in the USA. The detailed clarifications in collaboration with a renowned US law firm and their regulatory experts have shown that C-PTBE-01 meets the criteria for a Biologic License Application (BLA). If approved in the USA, this would result in a market protection of 12 years, significantly longer than the 7 years market protection under orphan drug status. This would extend the market protection for C-PTBE-01 in the USA by 70% or 5 years.
According to the US Public Health Service Act, the status of “biologic” is intended for peptides with a length of more than 40 amino acids. The molecule C-PTBE-01 has a length of 41 amino acids. The orphan drug designation for C-PTBE-01 will be pursued as planned.
About C-PTBE-01
Curatis is focusing its development activities for C-PTBE-01 on an very rare group of aggressive brain tumours (Diffuse Midline Glioma, DMG). These tumours mainly affect children, with most cases being diagnosed between the ages of 5 and 9. In the USA, around 800 patients are diagnosed with DMG every year; in Europe, the number is in the same order of magnitude, which is why the disease is considered a ‘rare disease’ for regulatory purposes.
In connection with DMG, indirect brain damage regularly occurs due to an accumulation of extracellular fluid in the vicinity of the tumour. This peritumoural brain edema (PTBE) can cause symptoms such as headaches, vomiting and neurological dysfunction such as paralysis, speech disorders, visual problems and altered mental status and can be life-threatening.
The current typical treatment method for PTBE is the use of corticosteroids. Corticosteroids often have serious side effects such as severe myopathies, muscle wasting, abnormal weight gain, osteoporosis, gastritis, gastrointestinal bleeding, hypertension and personality changes. The already serious side effects are exacerbated in children.
C-PTBE-01 has demonstrated a strong steroid-sparing effect in two clinical safety and efficacy studies, which may lead to a significant reduction or complete replacement of corticosteroid use and thus alleviation of the severe side effects associated with steroid use in children.
A detailed analysis of Curatis and its product candidates is available in a research report at https://ir.curatis.com/equity-research-reports.
About Curatis:
Curatis Holding AG is a publicly listed company (CURN.SW) specialising in the development and commercialisation of drugs for rare and very rare diseases. Curatis has a sales portfolio of more than 30 drugs and a pipeline of orphan drug products and speciality products that can make a significant contribution to cash flow from 2025 onwards. Further information can be found on the website www.curatis.com.
Disclaimer:
The information contained in this media release and in any link to our website indicated here is not for use in any country or jurisdiction or by any persons where such use would constitute a violation of law.
This media release contains "forward-looking statements" that are based on our current expectations, assumptions, estimates and projections about us and our industry. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain the words "may", "will", "should", "continue", "believe", "anticipate", "expect", "estimate", "intend", "project", "plan", "will likely continue", "will likely result", or words or phrases with similar meaning. Undue reliance should not be placed on such statements because, by their nature, forward-looking statements involve risks and uncertainties, including, without limitation, economic, competitive, governmental and technological factors outside the control of Curatis Group, that may cause Curatis' business, strategy or actual results to differ materially from the forward-looking statements (or from past results). For any factors that could cause actual results to differ materially from the forward-looking statements contained in this media release, please see our listing prospectus in connection with the business combination from April 2024. Curatis Group undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise. It should further be noted that past performance is not a guide to future performance.
The information contained in this media release is not an offer to sell or a solicitation of offers to purchase or subscribe for securities. This media release is not a prospectus within the meaning of the Swiss Financial Services Act nor a prospectus under any other applicable laws.
Some financial information in this media release has been rounded and, as a result, the figures shown as totals in this media release may slightly vary from the exact arithmetic aggregation of the figures that precede them.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113599004/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Clarity AI Joins Institutional Investors Group on Climate Change (IIGCC), Strengthening Its Role in Shaping Sustainable Investment Through Data and Expertise14.11.2024 10:05:00 CET | Press release
As a member, Clarity AI will engage in IIGCC’s working groups, learning and contributing its expertise to develop future investor guidance on key climate issues Clarity AI, the leading global sustainability tech company, announced today during COP29 that it has become an associate member of the Institutional Investors Group on Climate Change (IIGCC). This membership underscores Clarity AI's commitment to driving the sustainable investment market forward, empowering investors to address climate risk within their portfolios, and contributing to the global transition to a low-carbon economy. As part of its membership, Clarity AI looks forward to contributing its expertise in climate data needs and potential solutions to IIGCC's working groups, helping to shape future investor guidance on key climate issues. “Joining IIGCC is a significant step for Clarity AI as we continue our mission to help investors navigate the complexities of sustainable investment,” said Lorenzo Saa, Chief Sustainab
PUMA unveils Vision 2030: Scaling up for bigger impact in climate, circularity and human rights14.11.2024 09:00:00 CET | Press release
Sports company PUMA has announced its new Vision 2030 sustainability goals, which expand on the strong progress the brand has made. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114901121/en/ PUMA Headquarters at Herzogenaurach (Photo: Business Wire) “With Vision 2030 we have elevated and evolved our current 10FOR25 sustainability goals to achieve impact on a larger scale across our business in climate, circularity and human rights. We are setting the bar higher to stay true to our responsibility to be FOREVER. BETTER. throughout our business, for people and the planet,” said Anne-Laure Descours, Chief Sourcing Officer. PUMA has set new greenhouse gas reduction targets, which were approved by the Science Based Targets initiative (SBTi) as aligned with a 1.5-degree scenario. By 2030, PUMA seeks to cut its absolute Scope 1 and 2 greenhouse gas emissions by 90% (market based) from a 2017 baseline year and has committed to r
Murata HCR Redefines Automotive Timing Devices With the Total Frequency Tolerance of ±40PPM Under -40°C to +125°C Operation14.11.2024 03:00:00 CET | Press release
Murata Manufacturing Co., Ltd. (TOKYO:6981) (ISIN:JP3914400001) unveils a cutting-edge electronic timing device featuring exceptional accuracy ±40ppm and reliability even in wide-temperature -40°C to +125°C conditions. By addressing the limitations of current timing components in automotive electronic systems, it enhances the design and deployment of next-generation In-Vehicle Networks (IVN), wireless communication, and Advanced Driver Assistance Systems (ADAS) functions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113670074/en/ Murata Manufacturing Co., Ltd.: The new Timing Devices, XRCGE_M_F series (Photo: Business Wire) As the automotive industry continues to pursue greater integration and electronic downsizing to address the expanding number of critical electronic systems, the performance requirements for components are growing. In order to achieve tighter packaging without compromising accuracy, it is now necessar
SBC Medical Group Holdings Inc. Reports Third Quarter 2024 Financial Results13.11.2024 22:59:00 CET | Press release
SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 HighlightsTotal revenues for the three months ended September 30, 2024 were $53 million, representing an increase of 12% from $47 million in the same quarter of 2023. Total revenues for the nine months ended September 30, 2024 was $160 million, representing an increase of 23% from $131 million in the same period of 2023. Income from operations for the three months ended September 30, 2024 was $13 million, representing a decrease by 31% from the same quarter in 2023. This result was impacted by $12.8 million of stock-based compensation expense related to the Company’s listing process. Income from operations for the nine months ended September 30, 2024 was $65.5 million, representing an increase of
Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services13.11.2024 18:00:00 CET | Press release
Altasciences, a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services. This core business supports both preclinical and clinical studies conducted at Altasciences’ facilities, while also offering an extensive standalone solution to meet the diverse needs of clients. By delivering high-quality, flexible bioanalytical services, Altasciences remains dedicated to advancing drug development and empowering clients across every phase of research. For three decades now, Altasciences has taken pride in evolving their solutions to meet the needs of pharmaceutical and biotechnology companies of all sizes, including the expansion of their labs in Seattle, WA, Columbia, MO, and Laval, Québec. Their three state-of-the-art bioanalytical laboratories feature mirrored operations and uniform protocols to maintain consistency and quality across client projects, ensuring reliable, high-quality data regardless of location. This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom